EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Relaxin-2 reverses diastolic dysfunction and suppresses sustained arrhythmias in a rat model of Heart Failure with preserved Ejection Fraction (HFpEF)

Relaxin-2 kehrt diastolische Dysfunktion um und unterdrückt anhaltende Arrhythmien in einem Rattenmodell der Herzinsuffizienz mit erhaltener Ejektionsfraktion (HFpEF)

Joshua B Palma, Bethann Gabris-Weber, Brenda McMahon, Anthony J Mauro iD, Cynthia St Hilaire iD, Rolando A Cuevas iD, Thomas B Dschietzig iD, Guillermo Romero, Guy Salama iD

PLOS One · 12.11.2026 · 21 (11) · e0350373

DOI: 10.1371/journal.pone.0350373 ↗

Auf einen Blick

In einem Rattenmodell von HFpEF kehrte synthetisches humanes Relaxin-2 die diastolische Dysfunktion weitgehend um und unterdrückte anhaltende Arrhythmien. Auch hemodynamischer Stress nahm ab.

Fragestellung

Welche Effekte hat synthetisches humanes Relaxin-2 auf diastolische Dysfunktion und Arrhythmieanfälligkeit bei HFpEF?

Methode

Männliche ZSF1-Ratten erhielten Normaldiät oder High-Fat-Diät; nach Bestätigung von HFpEF wurden sie 2 Wochen lang mit Relaxin oder Vehikel behandelt. Danach erfolgten Echokardiographie, optische Kartierung, PES, IF und qPCR.

Ergebnisse

RLX verringerte LA-Dimensionen und E/e’. Bei HFpEF-Ratten unterdrückte RLX anhaltende atriale und ventrikuläre Arrhythmien (0/6 vs. 2/5), nicht jedoch nicht anhaltende Arrhythmien.

Schlussfolgerung der Autor:innen

Nach Ansicht der Autoren kehrte RLX die diastolische Dysfunktion, den hemodynamischen Stress und anhaltende Arrhythmien weitgehend um und zeigte potenzielles therapeutisches Potenzial bei HFpEF.

Kernaussagen

  • RLX verringerte LA-Dimensionen und E/e’.
  • Anhaltende atriale und ventrikuläre Arrhythmien wurden unterdrückt.
  • Wnt/canonische Signalwege und Genexpression veränderten sich.

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 12.11.2026. Verfasst von Joshua B Palma und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Heart and Vascular Institute, United States of America. Hauptthemen laut MEDLINE: Relaxin, Arrhythmias, Cardiac, Heart Failure, Stroke Volume. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, Samuel and Emma Winters Foundation, NHLBI Division of Intramural Research.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Heart failure with preserved ejection fraction (HFpEF) afflicts millions annually and current treatments provide symptomatic relief. The goal is to test the effects of synthetic human Relaxin-2 (RLX) on diastolic dysfunction (DD) and arrhythmia vulnerability. Methods and Results Male ZSF1 rats were placed on a normal diet (ND, N = 8 controls) or a high-fat diet (HFD, N = 11), resulting in the development of DD in 11-weeks, based on serial echocardiograms (enlarged left atrium (LA), wall thickness, doppler flow: E/e’). Once HFpEF was confirmed, ND and HFpEF rats were randomly treated with Relaxin (400 µg/kg/day RLX, N = 6) or the vehicle (N = 5) for 2-weeks using implanted minipumps. Echocardiograms were repeated for 2 more weeks, then hearts were isolated, optically mapped, subjected to programmed electrical stimulation (PES) and tissues dissected for immuno-fluorescence (IF), and qPCR analysis. Circulating levels of glucose, RLX and NT-pro-ANP were measured, pre- and post-treatment. Echocardiograms indicated that RLX reversed DD by reducing LA dimensions and E/e’. Optical mapping showed that vehicle-treated, ND rats (N = 3) had non-sustained atrial (1/3), and ventricular (3/3) arrhythmias and RLX-treatment reduced them to 0/3 and 1/3, respectively. Vehicle-treated, HFD rats had non-sustained (2/5) and sustained (2/5) atrial and ventricular arrhythmias (N = 5). RLX-treatment (N = 6) suppressed sustained atrial and ventricular arrhythmias (0/6) but not non-sustained atrial (2/6) and ventricular (3/6) arrhythmias. RLX tended to increase conduction velocity (CV), particularly at short cycle lengths consistent with increased Nav1.5, Connexin-43, β-catenin and Wnt1 expression, based on IF. There were no significant changes in fibrosis in this HFpEF model. NT-pro-ANP was elevated in HFpEF and reduced towards control values by RLX. qPCR analysis showed that RLX decreased Dickkopf (DKK1) and Matrix Metallopeptidase 1a (MMP1A) genes and increased SCN5A expression compared to vehicle (N = 6 and 5, respectively).

Conclusions

The ZSF1 model showed indications of HFpEF, including DD, enlargement of the LA, hemodynamic stress, increased vulnerability to sustained AF and VF, and elevated glucose and blood pressure. RLX treatment largely reversed DD, hemodynamic stress, and suppressed sustained arrhythmias. RLX elicited cardiac genomic changes, most likely through Wnt/canonical signaling, demonstrating RLX’s potential as a therapy for HFpEF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RelaxinArrhythmias, CardiacHeart FailureStroke VolumeAnimalsMaleRatsDisease Models, AnimalDiastoleConnexin 43Humans

Substanzen

RelaxinRLN2 protein, humanConnexin 43

Autor:innen und Institutionen

  • Department of Medicine, Heart and Vascular Institute, United States of America.
  • Vascular Medicine Institute, Pittsburgh, Pennsylvania, United States of America.
  • Cardiothoracic Surgery and Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
  • Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
  • Relaxera Pharmazeutische Gesellschaft mbH & Co. KG, Bensheim, Germany.
  • Department of Pharmacology & Chemical Biology, United States of America.

ORCID-Profile: Anthony J Mauro, Cynthia St Hilaire, Rolando A Cuevas, Thomas B Dschietzig, Guy Salama

Förderung

  • NHLBI NIH HHS
  • Samuel and Emma Winters Foundation
  • NHLBI Division of Intramural Research
  • Relaxera Pharmazeutsche

Zitieren

APA

Palma, J. B., Gabris-Weber, B., McMahon, B., Mauro, A. J., St Hilaire, C., Cuevas, R. A., Dschietzig, T. B., Romero, G., & Salama, G. (2026). Relaxin-2 reverses diastolic dysfunction and suppresses sustained arrhythmias in a rat model of Heart Failure with preserved Ejection Fraction (HFpEF). PLOS One, 21(11), e0350373. https://doi.org/10.1371/journal.pone.0350373

Vancouver

Palma JB, Gabris-Weber B, McMahon B, Mauro AJ, St Hilaire C, Cuevas RA, et al. Relaxin-2 reverses diastolic dysfunction and suppresses sustained arrhythmias in a rat model of Heart Failure with preserved Ejection Fraction (HFpEF). PLOS One. 2026;21(11):e0350373. doi:10.1371/journal.pone.0350373

BibTeX
@article{Palma2026,
  author = {Palma, Joshua B and Gabris-Weber, Bethann and McMahon, Brenda and Mauro, Anthony J and St Hilaire, Cynthia and Cuevas, Rolando A and Dschietzig, Thomas B and Romero, Guillermo and Salama, Guy},
  title = {Relaxin-2 reverses diastolic dysfunction and suppresses sustained arrhythmias in a rat model of Heart Failure with preserved Ejection Fraction (HFpEF)},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {11},
  pages = {e0350373},
  doi = {10.1371/journal.pone.0350373}
}
Kostenlos starten →